XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

XORTX Therapeutics (XRTX) announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026 – will ...

Choi notes that many of these lifestyle changes will not only reduce uric acid levels and the risk of recurrent gout but will also improve the health status of those with comorbidities ...

Pending FDA feedback, the Company will also seek FDA orphan drug designation (“ODD”) and NDA marketing approval for the XRx-026 program. Previously, oxypurinol was granted ODD for allopurinol ...

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. The company is actively involved in creating ...

Colchicine in combination with probenecid or allopurinol is frequently used to ... to colchicine and nonsteroidal antiinflammatory drugs (NSAIDs), systemic corticosteroids are typically given.

FOR centuries, gout has been a deeply misunderstood disease, associated only with jolly, indulgent, and often big men. When Henry VIII was diagnosed, it became firmly entrenched in popular belief ...

for several years in order to boost revenues during a tricky period when several big-selling drugs went off-patent. But in the case of Zurampic (lesinurad) and Duzallo (lesinurad + allopurinol ...

The goal of treatment is to reduce levels of uric acid in the blood below the 6 mg/dl threshold, but in some cases, current drugs like allopurinol and febuxostat aren’t able to achieve that ...

First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the ...

They’ll check your uric acid levels to diagnose your condition. Sometimes, they may prescribe a drug such as allopurinol (Zyloprim) or febuxostat (Uloric) to lower your uric acid levels.